


## **Piramal Critical Care Announces U.S. Launch of Chlorpromazine Hydrochloride for Injection, USP**

**Bethlehem, PA – January 24, 2025:** Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), today, announced the U.S. launch of Chlorpromazine Hydrochloride for Injection, USP, which will be offered in 25mg/1mL and 50mg/2 mL vials. With this launch, PCC continues to expand their generic injectables portfolio.



**Peter DeYoung, Chief Executive Officer of Piramal Global Pharma** commented: “We are excited to launch Chlorpromazine Hydrochloride for Injection, USP, which joins our growing U.S. portfolio of injectable products at Piramal Critical Care. It further complements our market-leading inhaled anesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”

The launch of Chlorpromazine Hydrochloride for Injection, USP (25mg/1mL and 50mg/2 mL vials) is the latest in a series of recent product launches from Piramal Critical Care in the generic injectables market. In 2024, PCC launched the first to market generic of Edaravone IV Infusion, which followed 2023 launches of Pantoprazole Sodium for Injection, USP and Doxycycline for Injection, USP to further enhance their wide portfolio of critical care products. For full prescribing information on Chlorpromazine Hydrochloride, please click here: [Full prescribing information available here.](#)

### **About Piramal Critical Care:**

Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy. Piramal Critical Care maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. Their product portfolio includes inhaled anesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. Piramal Critical Care has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations. In addition, Piramal Critical Care partners with leading pharmaceutical development and manufacturing organizations around the world.

For more information visit <http://www.PiramalCriticalCare.us> | [LinkedIn](#)



## **About Piramal Pharma Ltd:**

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17\* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information visit: [Piramal Pharma | LinkedIn](#)

## **For queries:**

Madiha Vahid

Lead – Media & PR

[Madiha.Vahid@piramal.com](mailto:Madiha.Vahid@piramal.com)

Gagan Borana

Investor Relations & Enterprise Risk Management

[Gagan.borana@piramal.com](mailto:Gagan.borana@piramal.com)

\*Includes one facility through minority investment in Yapan Bio

**Piramal Critical Care, Inc.**

3950 Schelden Circle, Bethlehem, Pennsylvania 18017-8936

Telephone: 610-974-9760 Fax: 610-861-4746

[piramalcriticalcare.com](http://piramalcriticalcare.com)